Clover Health Investments, Corp. (CLOV) P/E Ratio History
UndervaluedTrading at 216.1x vs 5Y avg 271.1x · 0th percentile · Below historical baseline · Data 2026–2026
Loading P/E history...
P/E Ratio Analysis
As of November 8, 2026, Clover Health Investments, Corp. (CLOV) trades at a price-to-earnings ratio of 216.1x, with a stock price of $4.82 and trailing twelve-month earnings per share of $0.02.
The current P/E is 20% below its 5-year average of 271.1x. Over the past five years, CLOV's P/E has ranged from a low of 271.1x to a high of 271.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 24.6x, CLOV trades at a 778% premium to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 196.0x.
Relative to the broader market, CLOV commands a significant premium over the S&P 500 median P/E of 21.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CLOV DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CLOV Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
CLOV P/E vs Peers
Health Insurers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $52B | 42.4 | - | -1% | |
| $107B | 9.8Lowest | - | -62% | |
| $92B | 18.0 | 2.61Best | -2% | |
| $34B | 23.6 | - | -316% | |
| $2B | 52.9 | - | +99%Best | |
| $8B | 12.4 | - | -1866% | |
| $358B | 22.4 | - | -15% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
CLOV Historical P/E Data (2026–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q3 | Sep 30 2026 | $4.31 | $0.02 | 271.1x | +0% |
Average P/E for displayed period: 271.1x
CLOV Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10-year return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CLOV — Frequently Asked Questions
Quick answers to the most common questions about buying CLOV stock.
What is CLOV's P/E ratio?
Clover Health Investments, Corp. (CLOV) trailing twelve-month P/E ratio is 216.1x, based on TTM diluted EPS of $0.02. The 5-year average P/E is 271.1x and the historical range spans 271.1x to 271.1x.
Is CLOV stock overvalued or undervalued?
CLOV trades at 216.1x P/E, below its 5-year average of 271.1x. At the 0th percentile of its historical range (271.1x–271.1x), the stock is priced at a discount to its own history.
Is CLOV stock expensive?
No, CLOV is not expensive on a historical basis. The current P/E of 216.1x is below the 5-year average of 271.1x and sits at the 0th percentile of its valuation range.
What is CLOV's historical P/E range?
Over the past 5 years, CLOV's P/E ratio has ranged from 271.1x to 271.1x, with a median of 271.1x and an average of 271.1x. The current P/E of 216.1x places the stock at the 0th percentile of this range. Full historical data spans 2026–2026.
How does CLOV's P/E compare to the S&P 500?
CLOV trades at 216.1x P/E versus the S&P 500 median of 21.8x. The 891% premium to the market typically reflects higher expected earnings growth or quality.
How does CLOV's valuation compare to Healthcare peers?
Clover Health Investments, Corp. P/E of 216.1x compares to the Healthcare sector median of 24.6x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is CLOV's PEG ratio?
CLOV PEG ratio is N/A, based on a P/E of 216.1x and EPS growth of -93.6%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is CLOV's earnings yield?
CLOV earnings yield is 0.46%, the inverse of its 216.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.